在具有EGFR突变的NSCLC中,外体非编码RNA介导的EGFR-TKI耐药性
Daoan Cheng1, Banglu Wang1, Lige Wu1
1Departments of Oncology, The Third Affiliated Hospital of Soochow University, Changzhou, 213004, China.
Medical oncology (Northwood, London, England)
|July 28, 2023
概括
携带非编码RNA (ncRNA) 的外基因组在非小细胞肺癌 (NSCLC) 中驱动对表皮生长因子受体氨酸激酶抑制剂 (EGFR-TKI) 的耐药性. 针对这些外体ncRNAs可能会克服肺癌患者的EGFR-TKI耐药性.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 遗传学 遗传学 是一个
背景情况:
- 肺癌是全球癌症死亡的主要原因之一.
- 皮肤上生长因子受体氨酸激酶抑制剂 (EGFR-TKI) 改善了EGFR突变非小细胞肺癌 (NSCLC) 的结局.
- 对EGFR-TKIs的获得性耐药性仍然是NSCLC治疗中的重大临床挑战.
研究的目的:
- 审查外体非编码RNAs (ncRNAs) 在EGFR突变NSCLC中对EGFR-TKIs中介性耐药性的作用.
- 提供关于这个主题的当前研究的全面概述.
- 突出外体ncRNAs作为生物标记物和治疗点的潜力.
主要方法:
- 对研究异体性ncRNA和EGFR-TKI在NSCLC中的耐药性的文献综述.
- 对外体内循环RNA (circRNAs),微RNA (miRNAs) 和长非编码RNA (lncRNAs) 的发现进行分析.
- 综合有关这些ncRNAs对抗性的机制的信息.
主要成果:
- 外基因组促进ncRNAs的细胞间转移,包括circRNA,miRNA和lncRNA.
- 这些外体ncRNAs在NSCLC中EGFR-TKI耐药性的发展和进展中发挥着至关重要的作用.
- 特定的外体ncRNA已被确定为抗性途径的关键媒介.
结论:
- 外体ncRNAs是EGFR-TKI在EGFR突变NSCLC中抵抗的关键参与者.
- 对外体ncRNAs的检测可以作为一种监测工具,用于针对NSCLC的向治疗疗效.
- 向外体ncRNAs是一个有希望的治疗策略,以克服耐药性并改善NSCLC患者的临床结果.
更多相关视频
09:38Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
Published on: June 26, 2019
8.0K
08:52Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids
Published on: November 22, 2021
4.1K
相关概念视频
02:38Mitogens and the Cell Cycle
6.6K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.6K
02:57Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K
02:39lncRNA - Long Non-coding RNAs
8.6K
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
8.6K
02:56Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K